DEC 1 7 2003

Sheet

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid DMB control number.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless I contains a valid DMB control number.

Complete if Known.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Application Number	10/627,994		
Filing Date	July 28, 2003		
First Named Inventor	BAUMANN, et al.		
Art Unit	1614		
Examiner Name	Unassigned		
Attorney Docket Number	81301.0001		

Examiner	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
Initials*		Number-Kind Code ^{2 (Floorin)}			
/ESO/		^{US-} 4,689,338	08-25-1987	Gerster, J.F.	
7ESO/		^{US-} 5,238,944	08-24-1993	Wick, S.M., et al.	
/ESO/		US- 6,147,086	11-14-2000	Brenman, S.A.	
		US-			1
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number * "Kind Code ⁶ (# known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
			MM-DD-YYYY			
/ESO/		WO 00/40228	07-13-2000			
						L
						L

|--|

"EXAMINET: Initial if reference considered, whicher or not cision is in conformance with MPEP 603. Draw the through clasted in this is conformance and not considered, included copy of this form with next communication to applicant "Applicants' unique science designation unique (circinal). *See Kinds Codes of USPTO Patent Documents at year, usging our wife PS 91.04. *Either Office that issued the document, by the two-letter code (WPD Standard ST3). *For year, and the communication of the year of the reging of the Emperor must preced the serial number of the appendix document, by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attention.

Inflamentaria distriction is equired by 37 CFR 197 and 1.88. The information is required to obtain or testin a benefit by the policy testin class of the control of the con

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DEC 1 7 2003

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

THE TRAPEST e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Compl t if Known stitute for form 1449/PTO Applicati n Number 10/627,994 Filing Date INFORMATION DISCLOSURE July 28, 2003 STATEMENT BY APPLICANT First Named Inventor BAUMANN, et al. Art Unit 1614 (Use as many sheets as necessary) Examiner Name Unassigned Attorney Docket Number Sheet 2 2 81301.0001 of

NON PATENT LITERATURE DOCUMENTS					
aminer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T²			
	IZUMI, T., et al.; TH-Imidazo(4,5-c)quinoline Derivatives as Novel Potent TNF-alpha Suppressors: Synthesis and Structure - Activity Relationship of 1, 2- and 4-Substituted 1H-imidazo(4,5-c)prinfolines or 1H-imidazo(4,5-c)prinfolines iBioorganic & Medicinal Chemistry 11, 2541-2550 (2003).				
	JURK, M., et al.; Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848, Nature immunology, Vol. 3, No. 6, p.499 (June 2002).				
/ESO/ MOORE, R.A., et al.; Imiquimod for the treatment of genital warts: a quantitative systematic review, BMC Infectious Diseases, Vol. 1, No. 3, 1471-2334 (2001).					
	STANLEY, M.A.; Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential, Clin Exp Dermatology, Vol. 27 No. 7, 571-7 (Abstract) (Oct. 2002).				
	STERRY, W., et al.; Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: nandomized studies comparing low-frequency dosing with and without occlusion, British Journal of Dermatology, Vol. 147, 1227-1285 (2002).				
	STOCKFLETH, E., et al.; Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod, European Journal of Dermatology, Vol. 12, 569-572 (2002).				
	van GALEN, P.J., et al.; 1H-Imidazo(4.5-c)quinolin-4-amines: Novel Non-Xanthine Adenosine Antagonists, J. Med. Chem., Vol. 34, 1202-1206 (1991).				
		include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. IZUMI, T., et al.: Himidazo(4,5-c)quinoline Derivatives as Novel Potent TNF-alpha Suppressors: Synthesis and Structure - Activity Retainoshe of 1-2, and 4-Substituted H-indiazo(4,5-c)quinolines or H-imidazo(4,5-c)quinolines or H-i			

Examiner	/Eric Olson/	Date	12/01/2008			
Signature		Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not						
considered. Include copy of this form with next communication to applicant.						

Date

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English tanguage Translation is attached.
This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the buffer which is to file (and by the USPTO to process) an application. Confidentially is governed by 38 U.S. C. 122 and 37 CFR 1.1.4. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Inframation Officer, U.S. Patient and Trademark Office, P.O. Box 1430, Adamsful, N.Z. 2023-1430, D.NOT SEND FEES OR CONFLETE OF CHIEF TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.